SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.
Smith & Nephew continues to demonstrate solid business recovery, with robust revenue, profit, and free cash flow growth across all divisions. SNN's 2026 outlook targets 6% underlying revenue growth, 8% organic trading profit growth, and $800 million in free cash flow, with a new $500 million share buyback announced. Completion of the 12-point plan delivered mixed results: revenue growth targets were met, but trading margin fell short, prompting a new 'RISE' strategy with 2028 financial targets.
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
| Health Care Equipment & Supplies Industry | Healthcare Sector | Deepak S Nath CEO | XDUS Exchange | US83175M2052 ISIN |
| GB Country | 17,818 Employees | 27 Mar 2026 Last Dividend | 16 Dec 2003 Last Split | 16 Nov 1999 IPO Date |
Smith & Nephew plc is a globally recognized company specializing in the development, manufacture, marketing, and sale of medical devices and services. Founded in 1856 and based in Watford, the United Kingdom, the company operates internationally, catering to the healthcare sector through its three main segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Smith & Nephew's mission is to improve the quality of life for people around the world by providing innovative and effective medical solutions.
Smith & Nephew offers a comprehensive range of medical devices and services across various specializations: